-
Revenue
-
Performance
Revenue by segment (%)
* Based on source of manufacture.
32%
of Group revenue
7%
of Group gross profit
- Europe CIS 90
- Australasia6
- Africa Middle East3
- Asia1
Revenue
| Revenue |
2024 R’million |
2023 R’million |
%Change Reported |
CER |
|---|---|---|---|---|
|
Finished dose form |
5 262 |
3 970 |
33 |
24 |
|
Active pharmaceutical ingredients |
5 102 |
5 024 |
2 |
(6) |
|
Heparin |
3 772 |
2 303 |
64 |
51 |
|
Total |
14 136 |
11 297 |
25 |
16 |
|
Gross profit percentage |
9,2 |
11,4 |
|
|
Manufacturing revenue grew significantly by 25%, partly aided by exchange rate tailwinds. All segments
experienced growth, with the FDF segment rising by 33%, supported by the contribution from third-party
contracts for sterile manufacturing. The Heparin segment surged by 64% following the strategic shift
towards toll manufacture. The API segment grew by a steady 2%.
The gross profit margin declined to 9,2%, down from 11,4% in FY2023 influenced by the higher Heparin sales mix following the transition to toll manufacture and the non-recurrence of grant funding enjoyed in the prior year. In the second half of the year, the margin improved to 12,3% benefiting from the higher sterile capacity fill contribution of more than the R500 million guided.
The gross profit margin declined to 9,2%, down from 11,4% in FY2023 influenced by the higher Heparin sales mix following the transition to toll manufacture and the non-recurrence of grant funding enjoyed in the prior year. In the second half of the year, the margin improved to 12,3% benefiting from the higher sterile capacity fill contribution of more than the R500 million guided.
